Long-Term Outcomes of Rheohaemapheresis in the Treatment of Dry Form of Age-Related Macular Degeneration

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F13%3A10192011" target="_blank" >RIV/00179906:_____/13:10192011 - isvavai.cz</a>
Alternative codes found
RIV/00843989:_____/13:E0103702 RIV/00216208:11150/13:10192011
Result on the web
<a href="http://www.hindawi.com/journals/joph/2013/135798/" target="_blank" >http://www.hindawi.com/journals/joph/2013/135798/</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1155/2013/135798" target="_blank" >10.1155/2013/135798</a>

Result language
angličtina
Original language name
Long-Term Outcomes of Rheohaemapheresis in the Treatment of Dry Form of Age-Related Macular Degeneration
Original language description
Purpose. Determining long-term effects of rheohaemapheresis on the dry form of age-related macular degeneration. Methods. This study evaluates 19 patients, average age of 67.6 years, treated with rheohaemapheresis and 18 patients, average age of 72.8 years, comprising the control group. Minimum follow up period was 3.5 years. Each treated patient received a series of 8 sessions of rheohaemapheresis of 1.5 plasma volumes within 10 weeks. We measured the drusenoid pigment epithelium detachment (DPED), best-corrected visual acuity (BCVA), electroretinography (ERG), and rheological parameters. Results. In the treatment group, the baseline BCVA was 0.74 (0.36-1.0) 95% CI and BCVA after 3.5 years was 0.79 (0.41-1.0) 95% CI ( ). In the control group, the baseline BCVA was 0.71 (0.15-1.0) 95% CI and BCVA after 3.5 years decreased to 0.7 (0.32-0.87) 95% CI ( ). Baseline DPED was 6.78 +- 3.79 mm2; after 3.5 years, it decreased to 4.13 +- 3.84 mm2 ( ). In the control group, the baseline DPED was
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FF - ENT (ie. ear, nose, throat), ophthalmology, dentistry
OECD FORD branch
—

Project
<a href="/en/project/NT14037" target="_blank" >NT14037: Rationalization of the systemic treatment of age-related macular degeneration with rheohemapheresis</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)